Somatostatin receptor manipulation

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Somatostatin receptors (ssts) are crucial for the diagnostic and therapeutic use of somatostatin analogues in human tumors.
• Understanding sst regulation is key to improving radioligand uptake and radiotherapy efficacy.
• Previous studies showed cell-type-specific sst regulation by agonists, glucocorticoids, and oestrogens in pituitary cell lines.

Purpose of the Study:

• To investigate the regulation of sst expression in a non-pituitary tumor model, specifically the 7315b rat prolactinoma.
• To determine the role of oestradiol (E2) in regulating sst (subtype) expression in this tumor model, both in vitro and in vivo.

Main Methods:

• Utilized the transplantable 7315b prolactin-secreting rat pituitary tumor model.
• Assessed sst expression (mRNA and protein) in vitro and in vivo.
• Administered oestradiol (E2) to tumor-bearing rats and measured sst2 mRNA expression.
• Measured serum prolactin (PRL) and E2 levels in tumor-bearing rats.

Main Results:

• The 7315b tumor is sst-negative in vivo but expresses sst2 and sst3 subtypes in vitro upon E2 addition.
• In vivo administration of E2 to tumor-bearing rats induced sst2 mRNA expression.
• 7315b-tumour-bearing rats showed undetectable serum E2 levels, suggesting ovarian E2 production inhibition by high PRL.
• The 7315b prolactinoma appears to down-regulate its own sst expression in vivo indirectly via the host's hormonal environment.

Conclusions:

• Oestradiol (E2) is a key regulator of somatostatin receptor (sst) expression in the 7315b rat prolactinoma model.
• The 7315b prolactinoma can down-regulate its sst expression in vivo, potentially due to E2 inhibition by high prolactin levels.
• This model may reflect the sst regulation observed in untreated human prolactinoma patients, explaining why some do not benefit from octreotide treatment.